CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis

by | Oct 17, 2017 | Press Releases | 0 comments

OXNARD, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE)